Lucid Diagnostics announced a public offering of 25 million shares at $1 each, aiming to raise approximately $25 million to support working capital and corporate purposes. The sequencing-based EsoGuard assay screens for esophageal adenocarcinoma via surface esophageal cells. The company anticipates an expanded cash runway of around three quarters post-offering and expects CMS coverage for EsoGuard, highlighting growing interest in esophageal cancer screening technologies.